Search results
Found 15 matches for
Colin Goding’s lab study the expression of ABCB5, with implications for drug resistance
Melanoma Genomic Instability increased by DNA damage remodelling the MITF interactome
Goding
6 February 2024
The Goding lab shows that Microphthalmia-associated Transcription Factor (MITF) plays a non-transcriptional role in shaping the DNA Damage Response programmes. MITF is phosphorylated on exposure to DNA damaging agents, and interacts with a DNA repair complex, increasing the level of genomic instability within cells which can have an impact on cancer initiation.
Insights made into how Red Hair Colour (RHC) trait variants may increase melanoma risk
Goding
30 November 2023
The Goding lab have worked in collaboration with Bill Pavan’s group of the National Human Genome Research Institute, at the National Institutes of Health (NIH), to uncover the transcriptomic profile of MC1R-inhibited melanocytes at single-cell resolution in Pigment Cell & Melanoma Research.
Ludwig Oxford DPhil candidate receives MSD Teaching Excellence Award
Goding
10 November 2023
Ludwig Oxford’s Olly Featherstone has been awarded an Early Career Excellent Teacher award by the Medical Sciences Division Teaching Excellence Awards.
Acetylation reprograms MITF target selectivity and residence time
Goding
28 September 2023
Ludwig Oxford’s Colin Goding and his lab reveal an acetylation-mediated switch that suppresses differentiation and provides an explanation of why a human K206Q MITF mutation is associated with Waardenburg syndrome.
Delving into MITF’s regulatory network in melanoma
Goding
18 July 2022
Research from Ludwig Oxford’s Colin Goding and Department of Oncology’s Francesca Buffa uncovers new genes regulated by MITF in the context of the melanoma tumour microenvironment.
Ludwig Oxford retreat 2022 – a recap
Barnes Boccellato Byrne Constantinescu De Val Goding Kriaucionis Lu Mehdipour Moura Alves Ratcliffe Schuster-Böckler Shi Song Van den Eynde
15 July 2022
On 13-14th June 2022, the Oxford Branch of the Ludwig Institute for Cancer Research held their annual retreat to discuss key scientific advances within the Branch and beyond.
CRUK Oxford Centre Development Fund awarded to Dr Romuald Binet
Goding
6 May 2022
Ludwig Oxford’s Dr Romuald Binet will investigate tissue-specific regulation of the DNA damage response in melanoma.
New view of a transcriptional regulator driving melanoma proliferation
Goding
25 November 2021
A study from Professor Colin Goding’s group finds an unexpected mechanism controlling growth vs senescence in cancer.
Investigating drug resistance in melanoma
Goding
28 September 2021
Ludwig Oxford’s Professor Colin Goding and Sao Paulo’s Professor Silvya Stuchi Maria-Engler show that TOP1 is involved in melanoma progression and adaptive resistance to treatment.
Understanding the role of BRN2 in melanoma
Goding
17 June 2021
A study from Professor Colin Goding’s group gives insight into the function of the BRN2 transcription factor in promoting melanoma initiation and metastasis.
Reporter assay to identify dormant cells
Goding
4 June 2021
Professor Colin Goding’s lab collaborate with colleagues in Germany to develop a new method to measure stem cell dormancy.
Insights into the two faces of AMPK, a key nutrient sensor
Goding
1 July 2020
Professor Colin Goding and colleagues reveal that a distinct metabolic environment in colon cancer cells allows AMPK to be activated by glucose to drive cancer proliferation, with implications for AMPK-targeting cancer drugs.
Debunking assumptions
Goding
11 June 2020
Researchers from Colin Goding’s lab demonstrate that weakening a transcription factor’s DNA binding affinity in vitro paradoxically increases its function in vivo.
Fatty acid metabolism in melanoma
Goding
14 November 2019
Colin Goding’s lab investigates how MITF regulates fatty acid metabolism in melanoma to control cell state-switching, an important contributor to cancer metastasis and therapy resistance.
Questioning melanoma disease state markers
Goding
10 October 2019
Colin Goding’s lab study the expression of ABCB5, with implications for drug resistance